Academic Commons


Serotonin Reuptake Inhibitor Use, Depression, and Long-Term Outcomes After an Acute Coronary Syndrome: A Prospective Cohort Study

Rieckmann, Nina; Kronish, Ian M.; Shapiro, Peter A.; Whang, William; Davidson, Karina W.

Depression is highly prevalent among patients with coronary heart disease.1 Selective serotonin reuptake inhibitors (SSRIs) are recommended as first-line antidepressant treatments for this population.2,3 Whereas there is a long-standing notion that SSRIs may improve cardiac disease prognosis by inhibiting platelet aggregation, SSRI use may also worsen prognosis by increasing bleeding4 or increasing the risk for arrhythmia.5

Only a few small randomized clinical trials with a total of 801 patients have assessed the efficacy of SSRIs in patients with a cardiac condition.6,7 Although no evidence for harm was detected in 2 meta-analyses, the follow-up periods for adverse cardiac events in these trials did not extend beyond 6 months, and patient samples were highly selected (ie, only patients not already receiving antidepressant therapy in usual care were included, and patients with comorbid conditions were excluded).

In a cohort of patients with acute coronary syndrome (ACS), we evaluated the association of SSRI and non-SSRI second-generation antidepressant use with the occurrence of cardiac events and mortality during a median follow-up period of 40 months.


  • thumnail for Rieckmann_JAMA_Intern_Med_2013_PMC.pdf Rieckmann_JAMA_Intern_Med_2013_PMC.pdf application/pdf 517 KB Download File

Also Published In

JAMA Internal Medicine

More About This Work

Academic Units
Center for Behavioral Cardiovascular Health
American Medical Association
Published Here
May 18, 2016
Academic Commons provides global access to research and scholarship produced at Columbia University, Barnard College, Teachers College, Union Theological Seminary and Jewish Theological Seminary. Academic Commons is managed by the Columbia University Libraries.